What is the clinical consequence of 'Slow Acetylator' status in a patient taking Isoniazid for tuberculosis?
Show answer and explanation
Correct answer: Increased risk of peripheral neuropathy and toxicity
Acetylation (a Phase II reaction) is the primary pathway for Isoniazid. Slow acetylators have a genetic deficiency in the enzyme NAT2, leading to higher plasma concentrations of the drug and a greater risk of adverse effects.
Keep practicing
More Drug Metabolism questions
- Which enzyme is responsible for the hydrolysis of the local anesthetic Procaine and the neuromuscular blocker Succinylcholine in the plasma?
- What happens during the 'De-alkylation' of a drug molecule?
- Biliary excretion of a drug metabolite can sometimes lead to 'Enterohepatic Recirculation'. This occurs when:
- The term 'Vmax' in enzyme kinetics refers to:
- Which factor is most likely to decrease hepatic drug metabolism in an elderly patient?
- What is the primary goal of drug metabolism (biotransformation) in the body?